Gainers
Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
Phreesia (NYSE:PHR) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.61) by 24.59 percent. This is a 65.22 percent decrease over losses of $(0.46) per share from the same